22.7% weight loss yet Novo Nordisk stock drops 27%
Novo Nordisk's new CagriSema drug showed weight loss results that are *stunning*, but less than what Wall Street expected.
Novo Nordisk (maker of Ozempic, Wegovy) had a rough day in the stock market on Friday. GLP1 receptor agonists have been incredibly effective so far, but there is still tremendous pressure on drug companies to produce ever better formulations and achieve even more weight loss.
Reuters reported on the massive 27% plunge in Novo Nordik's stock price:
Want to read more about Novo's new drug CagriSema and it's results along with the trials coming up?
The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:
